Rybrevant home page

ืœืื—ืจ ืฉื”ืื•ื ืงื•ืœื•ื’ ื”ืžืœื™ืฅ ืœืš ืื• ืœื‘ืŸ ืžืฉืคื—ืชืš ืขืœ ื”ื˜ื™ืคื•ืœ ื‘ืจื™ื™ื‘ืจื‘ื ื˜, ื™ืฉ ื—ืฉื™ื‘ื•ืช ืจื‘ื” ืœื“ื™ื•ื•ื— ื•ืฉื™ืชื•ืฃ ื”ืฆื•ื•ืช ื”ืจืคื•ืื™ ื‘ื›ืœ ืฉื™ื ื•ื™ ื‘ืชื—ื•ืฉื•ืชื™ืš ื‘ืžื”ืœืš ืชืงื•ืคืช ื”ื˜ื™ืคื•ืœ, ื˜ื™ืคื•ืœ ืžื•ืงื“ื ื‘ืชื•ืคืขื” ื™ืžื ืข ืืช ื”ื—ืžืจืชื”.
ื”ืžื™ื“ืข ืฉืœืคื ื™ืš ื™ืกื™ื™ืข ืœืš ืœืœืžื•ื“ ืขืœ ื”ื˜ื™ืคื•ืœ ื‘ืจื™ื™ื‘ืจื‘ื ื˜.

ืžื”ื• ืจื™ื™ื‘ืจื‘ื ื˜(ืืžื™ื‘ื ื˜ืžืื‘) ?


ืจื™ื™ื‘ืจื‘ื ื˜ ื”ื•ื ื˜ื™ืคื•ืœ ื‘ื™ื•ืœื•ื’ื™, ื ื•ื’ื“ืŸ ื“ื•-ืจืืฉื™, ืจืืฉื•ืŸ ืžืกื•ื’ื• ืœื˜ื™ืคื•ืœ ื‘-NSCLC, ืกืจื˜ืŸ ืจื™ืื” ืžืกื•ื’ ืชืื™ื ืœื ืงื˜ื ื™ื

ืจื™ื™ื‘ืจื‘ื ื˜ ื ืžืฆื ื™ืขื™ืœ ื‘ืžืฆื‘ื™ื ื‘ื”ื ื”ืžื—ืœื” ืœื ื ืชื™ื—ื” ื•/ืื• ื™ืฉื ื” ื”ืชืคืฉื˜ื•ืช ืฉืœ ื’ืจื•ืจื•ืช ื•ืžืชืืคื™ื™ื ืช ื‘ืžื•ื˜ืฆื™ื” ืžืกื•ื’ ื”ื•ืกืคื” ื‘-EGFR ืืงืกื•ืŸ 20

ืจื™ื™ื‘ืจื‘ื ื˜ ื™ื™ื ืชืŸ ื›ืืฉืจ ื™ืฉ ื”ืชืงื“ืžื•ืช ืžื—ืœื” ืชื•ืš ื›ื“ื™ ืื• ืœืื—ืจ ื˜ื™ืคื•ืœ ื›ื™ืžื•ืชืจืคื™ ืžื‘ื•ืกืก ืคืœื˜ื™ื ื•ื, ื‘ืžืงืจื™ื ื‘ื”ื ื™ืฉ ืกืจื˜ืŸ ืจื™ืื” ืžืกื•ื’ NSCLC ืขื EGFR ื—ื™ื•ื‘ื™ ืขื ืžื•ื˜ืฆื™ื” ืžืกื•ื’ ื”ื•ืกืคื” ื‘ืืงืกื•ืŸ 20

ื”ื˜ื™ืคื•ืœ ื‘ืจื™ื™ื‘ืจื‘ื ื˜ ืื•ืฉืจ ืขืœ ื™ื“ื™ ื”ืจืฉื•ื™ื•ืช (ืžืฉืจื“ ื”ื‘ืจื™ืื•ืช ื”ื™ืฉืจืืœื™, FDA ื•-EMA) ื•ื”ื•ื›ืœืœ ื‘ื”ื ื—ื™ื•ืช ื”ื‘ื™ื ืœืื•ืžื™ื•ืช ืœื˜ื™ืคื•ืœ ื‘ืงื• ื”ืฉื ื™ ื‘ืกืจื˜ืŸ ืจื™ืื” ืขื EGFR ื—ื™ื•ื‘ื™ ืžืกื•ื’ ืžื•ื˜ืฆื™ื™ืช ื”ื•ืกืคื” ื‘ืืงืกื•ืŸ 20.

ื”ื ื›ื ืžื•ื–ืžื ื™ื ืœืฆืคื•ืช ื‘ื“ืจ' ื”ื“ืก ื’ื ืฅ, ืื•ื ืงื•ืœื•ื’ื™ืช ื‘ื›ื™ืจื”, ืžื•ืžื—ื™ืช ืœืกืจื˜ืŸ ืจื™ืื” ื•ื’ื™ื“ื•ืœื™ ื‘ื™ืช ื—ื–ื”, ื”ืžืจื›ื– ื”ืจืคื•ืื™ ืฉื™ื‘ื ืชืœ ื”ืฉื•ืžืจ, ืืฉืจ ืžืกื‘ื™ืจื” ืขืœ ืจื™ื™ื‘ืจื‘ื ื˜

ืื™ืš ืจื™ื™ื‘ืจื‘ื ื˜ ืขื•ื‘ื“?


ื”ื›ื•ื•ื ืช ืžืขืจื›ืช ื”ื—ื™ืกื•ืŸ ืœืชืงื™ืคืช ืชืื™ ื”ื’ื™ื“ื•ืœ
ืœืจื™ื™ื‘ืจื‘ื ื˜ ื™ืฉ ื–ื™ืงื” ื’ื‘ื•ื”ื” ืœืชืื™ ืžืขืจื›ืช ื”ื—ื™ืกื•ืŸ ืืฉืจ ื’ื•ืจืžืช ืœื”ื›ื•ื•ื ืชื ืœืื–ื•ืจ ื”ื’ื™ื“ื•ืœ, ื–ื™ื”ื•ื™ ื”ืชืื™ื ื”ืกืจื˜ื ื™ื™ื ื•ืชืงื™ืคืชื.

ืคื™ืจื•ืง ื”ืงื•ืœื˜ื ื™ื ืžืกื•ื’ EGFR ื•-MET
ื”ืงื™ืฉื•ืจ ืฉืœ ืจื™ื™ื‘ืจื‘ื ื˜ ืœื—ืœื‘ื•ื ื™ ื”-EGFR ื•ื”-MET ืขืœ ื’ื‘ื™ ื”ืชื ื”ืกืจื˜ื ื™ ืžื•ื‘ื™ืœ ืœืคืจื•ืง ื”ื—ืœื‘ื•ื ื™ื ื•ื›ืš ืœืคื’ื™ืขื” ื‘ื™ื›ื•ืœืช ื”ืชื ื”ืกืจื˜ื ื™ ืœื’ื“ื•ืœ ื•ืœื”ืชืจื‘ื•ืช.

ืขื™ื›ื•ื‘ ืคืขื•ืœืช ื”ืงื•ืœื˜ื ื™ื ืžืกื•ื’ EGFR ื•-MET ื•ื—ืกื™ืžืชื
ื›ืืฉืจ ืจื™ื™ื‘ืจื‘ื ื˜ ื ืงืฉืจ ืœืงื•ืœื˜ื ื™ EGFR ื•ื”-MET ืขืœ ื’ื‘ื™ ืชืื™ ื”ื’ื™ื“ื•ืœ ื”ื•ื ืžืคื—ื™ืช ืืช ืคืขื™ืœื•ืชื ื•ืคื•ื’ืข ื‘ื™ื›ื•ืœืชื ืฉืœ ืชืื™ ื”ื’ื™ื“ื•ืœ ืœืฉืจื•ื“ ื•ืœื”ืชืจื‘ื•ืช.

ืžื—ืœืช ืกืจื˜ืŸ ื”ืจื™ืื”


ืžื”ื• ืกืจื˜ืŸ ืจื™ืื”?
ื›ืืฉืจ ืชืื™ ืจื™ืื” ื‘ืจื™ืื™ื ืžืฉืชื ื™ื ื•ืžืชื—ื™ืœื™ื ืœื”ืชื—ืœืง ืœืœื ื‘ืงืจื” ื”ื ื”ื•ืคื›ื™ื ืœืชืื™ื ืกืจื˜ื ื™ื™ื. ื”ืžืฉืš ื”ืชืจื‘ื•ืช ืฉืœ ืชืื™ื ืืœื• ื™ื™ืฆื•ืจ ื’ื™ื“ื•ืœื™ื ืกืจื˜ื ื™ื™ื.

ื‘ืžื—ืœื” ื’ืจื•ืจืชื™ืช
ื”ืชืื™ื ื”ืกืจื˜ื ื™ื™ื ื ืคืจื“ื™ื ืžื”ื’ื™ื“ื•ืœ ื”ืจืืฉื•ื ื™, ืžืชืคืฉื˜ื™ื ื‘ืื™ื‘ืจื™ื ืฉื•ื ื™ื ื‘ื’ื•ืฃ ื•ื™ื•ืฆืจื™ื ื’ื™ื“ื•ืœื™ื ื—ื“ืฉื™ื ืฉืžื”ื•ื•ื™ื ื’ืจื•ืจื•ืช.

ืกืจื˜ืŸ ืจื™ืื” ืžืกื•ื’ ืชืื™ื ืœื ืงื˜ื ื™ื NSCLC (Non-Small Cell Lung Cancer) โ€“ ื”ื•ื ื”ืกื•ื’ ื”ื ืคื•ืฅ ื‘ื™ื•ืชืจ ืžื‘ื™ืŸ ื›ืœืœ ืกืจื˜ื ื™ ื”ืจื™ืื”.


EGFR (Epithelial Growth Factor Receptor)
ื—ืœื‘ื•ืŸ ืžืกื•ื’ ืงื•ืœื˜ืŸ ื”ื ืžืฆื ืขืœ ื’ื‘ื™ ืชืื™ื ื‘ืจื™ืื™ื ื•ืกืจื˜ื ื™ื™ื ื•ืชืคืงื™ื“ื• ืœืขื•ื“ื“ ืชืื™ื ืœื”ืชืจื‘ื•ืช ื•ืœืฉืจื•ื“.

ื‘ืžืฆื‘ ืฉืœ ืžื—ืœื” ืžืžืืจืช
ืžืชืจื—ืฉ ืฉื™ื ื•ื™ ื’ื ื•ืžื™ (ืžื•ื˜ืฆื™ื”) ื‘ื—ืœื‘ื•ืŸ ื”-EGFR ืฉืžืชื—ื™ืœ ืœืขื‘ื•ื“ ืœืœื ื‘ืงืจื” ื•ื›ืš ืชืื™ ื”ืจื™ืื” ื”ื•ืคื›ื™ื ืœืกืจื˜ื ื™ื™ื ื•ืžืชืจื‘ื™ื ืœืœื ื”ืคืกืงื”.

ืžื•ื˜ืฆื™ื” ืžืกื•ื’ ื”ื•ืกืคื” ื‘ืืงืกื•ืŸ 20
ืกื•ื’ ืžืกื•ื™ื™ื ืฉืœ ืžื•ื˜ืฆื™ื” ื‘ื—ืœื‘ื•ืŸ EGFR, ื˜ื™ืคื•ืœื™ื ืจื‘ื™ื ืขืฉื•ื™ื™ื ืฉืœื ืœื”ื™ื•ืช ื™ืขื™ืœื™ื ื‘ืžื—ืœื” ื”ืžืื•ืคื™ื™ื ืช ื‘ืžื•ื˜ืฆื™ื” ืžืกื•ื’ ื–ื”.


NGS (Next Generation Sequencing)
ื‘ื™ืฉืจืืœ ื›ืœ ืžื˜ื•ืคืœ/ืช ืกืจื˜ืŸ ืจื™ืื” ื’ืจื•ืจืชื™ ื–ื›ืื™/ืช ืœื‘ืฆืข ื‘ื“ื™ืงื” ื’ื ื•ืžื™ืช ืžืงื™ืคื” ื‘ืžืกื’ืจืช ืกืœ ื”ื‘ืจื™ืื•ืช.

ืงื™ืฉื•ืจื™ื ืฉื™ืžื•ืฉื™ื™ื

ืืชืจ ืžืฉืจื“ ื”ื‘ืจื™ืื•ืช
ื”ืขืžื•ืชื” ื”ื™ืฉืจืืœื™ืช ืœืกืจื˜ืŸ ืจื™ืื”
ืžืชื—ื ืœื“ืขืช ื™ื•ืชืจ

ืงื™ืฉื•ืจ ื–ื” ื™ืขื‘ื™ืจ ืื•ืชืš ืœืืชืจ ืื—ืจ, ืืฉืจ ื’'ื•ื ืกื•ืŸ ืื ื“ ื’'ื•ื ืกื•ืŸ ืื™ื ื” ืื—ืจืื™ืช ืขืœ ืชื•ื›ื ื• ื•ืืฉืจ ืžื“ื™ื ื™ื•ืช ื”ืคืจื˜ื™ื•ืช ืฉืœื ื• ืื™ื ื” ื—ืœื” ืขืœื™ื•. ืื ื• ืžืžืœื™ืฆื™ื ืœืš ืœืงืจื•ื ืืช ืžื“ื™ื ื™ื•ืช ื”ืคืจื˜ื™ื•ืช ืฉืœ ื›ืœ ืืชืจ ืฉืืชื” ืžื‘ืงืจ ื‘ื•.


References
1. Rybrevant Israel MOH PI https://israeldrugs.health.gov.il/#!/medDetails/169%2046%2036954%2000
2. Park K et al. J Clin Oncol 2021. 39(30): 3391โ€“3402.
3. Grugan K et al. MAbs 2017; 9 114โ€“126.
4. Neijssen J et al. J Biol Chem 2021. 296 (100641); 1โ€“13.
5. Vijayaraghavan S et al. Mol Can Ther 2020; 19(10): 2044โ€“2056.
6. Yun J et al. Cancer Discovery 2020; 10(8): 1194โ€“1209.
7. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated
8. https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant
9. NCCN NSCLC Guidelines. Version 3.2023
10. IASLC atlas of molecular testing for targeted therapy in lung cancer 2.2023
11. L.E. Hendriks, et al. Annals of Oncology January 2023
12. ASCO guidelines: Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations Living Guideline
13. Rybrevant US patient's website: https://www.rybrevant.com/